Sequenom's CEO 'Puzzled' by Illumina's Buy of Verinata, Lays out 2013 Goals at JP Morgan | GenomeWeb

This article has been updated from a previous version to clarify the company's reimbursement goals for 2013.

SAN FRANCISCO (GenomeWeb News) – Sequenom Chairman and CEO Harry Hixson on Wednesday expressed confusion over Illumina's decision to acquire Verinata for a price that could climb to $450 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.